CDIP1

Summary

CDIP1 (cell death inducing p53 target 1, HGNC:13234) is a protein-coding gene on chromosome 16p13.3, encoding Cell death-inducing p53-target protein 1 (Q9H305). Acts as an important p53/TP53-apoptotic effector.

Predicted to enable zinc ion binding activity. Acts upstream of or within intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator. Located in cytoplasmic side of late endosome membrane; cytoplasmic side of lysosomal membrane; and nucleus.

Source: NCBI Gene 29965 — RefSeq curated summary.

At a glance

• GWAS associations: 9
• Clinical variants (ClinVar): 44 total
• MANE Select transcript: NM_013399

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:13234
Approved symbol	CDIP1
Name	cell death inducing p53 target 1
Location	16p13.3
Locus type	gene with protein product
Status	Approved
Aliases	CDIP, LITAFL
Ensembl gene	ENSG00000089486
Ensembl biotype	protein_coding
OMIM	610503
Entrez	29965

Gene structure

Transcript identifiers

Ensembl transcripts: 38 — 36 protein_coding, 1 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000399599, ENST00000562334, ENST00000562579, ENST00000563186, ENST00000563332, ENST00000563507, ENST00000564828, ENST00000566234, ENST00000567695, ENST00000586728, ENST00000586768, ENST00000588381, ENST00000589159, ENST00000589890, ENST00000857432, ENST00000857433, ENST00000857434, ENST00000857435, ENST00000857436, ENST00000857437, ENST00000857438, ENST00000857439, ENST00000857440, ENST00000857441, ENST00000857442, ENST00000857443, ENST00000857444, ENST00000857445, ENST00000857446, ENST00000857447, ENST00000857448, ENST00000921885, ENST00000921886, ENST00000921887, ENST00000921888, ENST00000921889, ENST00000945079, ENST00000945083

RefSeq mRNA: 4 — MANE Select: NM_013399 NM_001199054, NM_001199055, NM_001199056, NM_013399

CCDS: CCDS42114, CCDS58419, CCDS58420

Canonical transcript exons

ENST00000567695 — 6 exons

Exon	Start	End
ENSE00000363280	4512791	4513064
ENSE00001145764	4514575	4514664
ENSE00002579466	4538702	4538773
ENSE00002582551	4510669	4512683
ENSE00003562425	4514046	4514144
ENSE00003628267	4513696	4513851

Expression profiles

Bgee: expression breadth ubiquitous, 134 present calls, max score 98.19.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 47.5596 / max 883.7407, expressed in 1686 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
156100	38.5532	1683
156098	3.3489	861
156097	3.2425	589
156101	1.6100	774
156099	0.5876	381
156094	0.1910	79
156093	0.0264	8

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
prefrontal cortex	UBERON:0000451	98.19	gold quality
right frontal lobe	UBERON:0002810	98.16	gold quality
frontal cortex	UBERON:0001870	98.13	gold quality
primary visual cortex	UBERON:0002436	98.00	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	97.93	gold quality
Brodmann (1909) area 9	UBERON:0013540	97.90	gold quality
superior frontal gyrus	UBERON:0002661	97.88	gold quality
anterior cingulate cortex	UBERON:0009835	97.81	gold quality
cerebral cortex	UBERON:0000956	97.77	gold quality
nucleus accumbens	UBERON:0001882	97.73	gold quality
hypothalamus	UBERON:0001898	97.56	gold quality
putamen	UBERON:0001874	97.48	gold quality
caudate nucleus	UBERON:0001873	97.38	gold quality
right hemisphere of cerebellum	UBERON:0014890	97.37	gold quality
temporal lobe	UBERON:0001871	97.36	gold quality
amygdala	UBERON:0001876	97.35	gold quality
brain	UBERON:0000955	97.19	gold quality
cerebellum	UBERON:0002037	97.19	gold quality
cerebellar hemisphere	UBERON:0002245	97.19	gold quality
cerebellar cortex	UBERON:0002129	97.17	gold quality
Ammon’s horn	UBERON:0001954	97.12	gold quality
substantia nigra	UBERON:0002038	96.87	gold quality
apex of heart	UBERON:0002098	95.69	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	95.25	gold quality
adenohypophysis	UBERON:0002196	95.11	gold quality
pituitary gland	UBERON:0000007	94.90	gold quality
heart left ventricle	UBERON:0002084	93.91	gold quality
adult mammalian kidney	UBERON:0000082	93.37	gold quality
ventricular zone	UBERON:0003053	92.46	gold quality
ganglionic eminence	UBERON:0004023	92.45	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.64

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

77 targeting CDIP1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-4673	100.00	66.64	1490
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-4645-5P	99.98	65.81	1284
HSA-MIR-4715-3P	99.98	66.03	670
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-128-3P	99.95	71.17	2484
HSA-MIR-216A-3P	99.95	71.19	2505
HSA-MIR-4760-3P	99.93	70.50	2385
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-3681-3P	99.88	70.46	2254
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-6715A-3P	99.83	68.05	1473
HSA-MIR-205-5P	99.81	70.05	1557
HSA-MIR-3934-3P	99.76	65.51	1351
HSA-MIR-6764-5P	99.75	67.89	2304

Literature-anchored findings (GeneRIF, showing 6)

• These findings support a novel p53 –> CDIP –> TNF-alpha apoptotic pathway that directs apoptosis after exposure of cells to genotoxic stress. (PMID:17599062)
• CDIP expression correlates with sensitivity of cancer cells with TNFalpha, and CDIP seems to be a regulator of the p53-mediated death versus survival response of cells to TNFalpha. (PMID:22549949)
• Study conclude that LITAF is a monotopic membrane protein whose membrane integration is stabilised by a zinc finger. The related human protein, CDIP1 (cell death involved p53 target 1), displays identical membrane topology, suggesting that this mode of membrane integration is conserved in LITAF family proteins. (PMID:27582497)
• The Novel ALG-2 Target Protein CDIP1 Promotes Cell Death by Interacting with ESCRT-I and VAPA/B. (PMID:33503978)
• Role of ELK1 in regulating colorectal cancer progression: miR-31-5p/CDIP1 axis in CRC pathogenesis. (PMID:37547727)
• Cytoprotective Role of Autophagy in CDIP1 Expression-Induced Apoptosis in MCF-7 Breast Cancer Cells. (PMID:38928226)

Cross-species orthologs

14 orthologs

Organism	Symbol	Gene ID
danio_rerio	cdip1	ENSDARG00000076118
mus_musculus	Cdip1	ENSMUSG00000004071
rattus_norvegicus	Cdip1	ENSRNOG00000003328
drosophila_melanogaster	CG12645	FBGN0030181
drosophila_melanogaster	CG13510	FBGN0034758
drosophila_melanogaster	CG4250	FBGN0034761
drosophila_melanogaster	CG13516	FBGN0040658
drosophila_melanogaster	CG30269	FBGN0050269
drosophila_melanogaster	CG30273	FBGN0050273
caenorhabditis_elegans		WBGENE00012548
caenorhabditis_elegans		WBGENE00012748
caenorhabditis_elegans		WBGENE00017513
caenorhabditis_elegans		WBGENE00021253
caenorhabditis_elegans	Y87G2A.19	WBGENE00044260

Paralogs (1): LITAF (ENSG00000189067)

Protein

Protein identifiers

Cell death-inducing p53-target protein 1 — Q9H305 (reviewed: Q9H305)

Alternative names: Cell death involved p53-target, Cell death-inducing protein, LITAF-like protein, Lipopolysaccharide-induced tumor necrosis factor-alpha-like protein, Transmembrane protein I1

All UniProt accessions (9): Q9H305, H3BRY7, H3BTN7, H3BTX4, K7EK15, K7ELR4, K7EM67, K7ENR4, K7ESA8

UniProt curated annotations — full annotation on UniProt →

Function. Acts as an important p53/TP53-apoptotic effector. Regulates TNF-mediated apoptosis in a p53/TP53-dependent manner.

Subcellular location. Late endosome membrane. Lysosome membrane.

Tissue specificity. Highly expressed in brain. Expressed at lower level in heart, skeletal muscle, kidney, pancreas and liver. Weakly or not expressed in placenta and lung.

Domain organisation. The LITAF domain is stabilized by a bound zinc ion. The LITAF domain contains an amphipathic helix that mediates interaction with lipid membranes.

Induction. Up-regulated by p53/TP53.

Miscellaneous. May be due to competing acceptor splice site.

Similarity. Belongs to the CDIP1/LITAF family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q9H305-1	1	yes
Q9H305-2	2
Q9H305-3	3

RefSeq proteins (4): NP_001185983, NP_001185984, NP_001185985, NP_037531* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR006629	LITAF	Domain
IPR037519	LITAF_fam	Family

Pfam: PF10601

UniProt features (13 total): binding site 4, splice variant 2, region of interest 2, compositionally biased region 2, chain 1, domain 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9H305-F1	55.37	0.00

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (4): 142; 145; 194; 197

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 162 (showing top): GGGACCA_MIR133A_MIR133B, GOBP_INTRINSIC_APOPTOTIC_SIGNALING_PATHWAY_IN_RESPONSE_TO_DNA_DAMAGE_BY_P53_CLASS_MEDIATOR, GOCC_VACUOLAR_MEMBRANE, TTTGTAG_MIR520D, LINDGREN_BLADDER_CANCER_CLUSTER_3_DN, LUCAS_HNF4A_TARGETS_UP, GOCC_MICROTUBULE_ORGANIZING_CENTER, SHEDDEN_LUNG_CANCER_GOOD_SURVIVAL_A5, GOBP_APOPTOTIC_SIGNALING_PATHWAY, BLALOCK_ALZHEIMERS_DISEASE_UP, GOCC_CENTROSOME, GOBP_INTRINSIC_APOPTOTIC_SIGNALING_PATHWAY_IN_RESPONSE_TO_DNA_DAMAGE, SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_DN, GOBP_DNA_DAMAGE_RESPONSE, GOBP_INTRINSIC_APOPTOTIC_SIGNALING_PATHWAY

GO Biological Process (2): intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator (GO:0042771), apoptotic process (GO:0006915)

GO Molecular Function (3): zinc ion binding (GO:0008270), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (8): nucleus (GO:0005634), cytoplasmic side of late endosome membrane (GO:0098560), cytoplasmic side of lysosomal membrane (GO:0098574), lysosome (GO:0005764), lysosomal membrane (GO:0005765), endosome (GO:0005768), membrane (GO:0016020), late endosome membrane (GO:0031902)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
intrinsic apoptotic signaling pathway in response to DNA damage	1
intrinsic apoptotic signaling pathway by p53 class mediator	1
programmed cell death	1
apoptotic signaling pathway	1
execution phase of apoptosis	1
transition metal ion binding	1
binding	1
cation binding	1
intracellular membrane-bounded organelle	1
cytoplasmic side of endosome membrane	1
late endosome membrane	1
lysosomal membrane	1
cytoplasmic side of membrane	1
lytic vacuole	1
lysosome	1
lytic vacuole membrane	1
endomembrane system	1
cytoplasmic vesicle	1
cellular anatomical structure	1
late endosome	1
endosome membrane	1

Protein interactions and networks

STRING

555 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CDIP1	BCAP31	P51572	943
CDIP1	ITCH	Q96J02	470
CDIP1	LGALS1	P09382	463
CDIP1	NEDD4	P46934	462
CDIP1	OR2C1	O95371	440
CDIP1	SRP68	Q9UHB9	413
CDIP1	DDX47	Q9H0S4	403
CDIP1	CARHSP1	Q9Y2V2	402
CDIP1	MTFP1	Q9UDX5	400
CDIP1	SLC8A1	P32418	400
CDIP1	KANK2	Q63ZY3	386
CDIP1	XRCC6	P12956	381
CDIP1	BPTF	Q12830	378
CDIP1	APOBEC3H	Q6NTF7	376
CDIP1	IGFALS	P35858	374

IntAct

45 interactions, top by confidence:

A	B	Type	Score
CDIP1	TNIP1	psi-mi:“MI:0915”(physical association)	0.670
TNIP1	CDIP1	psi-mi:“MI:0915”(physical association)	0.670
DESI1	CDIP1	psi-mi:“MI:0915”(physical association)	0.600
CDIP1	UBQLN1	psi-mi:“MI:0915”(physical association)	0.560
LAT	CDIP1	psi-mi:“MI:0915”(physical association)	0.560
CDIP1	UBQLN2	psi-mi:“MI:0915”(physical association)	0.560
EPN2	CDIP1	psi-mi:“MI:0915”(physical association)	0.560
OTUB2	CDIP1	psi-mi:“MI:0915”(physical association)	0.560
TOLLIP	CDIP1	psi-mi:“MI:0915”(physical association)	0.560
UBB	CDIP1	psi-mi:“MI:0915”(physical association)	0.560
UBC	CDIP1	psi-mi:“MI:0915”(physical association)	0.560
OTUD7B	CDIP1	psi-mi:“MI:0915”(physical association)	0.560
DCUN1D1	CDIP1	psi-mi:“MI:0915”(physical association)	0.560
NEDD4	CDIP1	psi-mi:“MI:0407”(direct interaction)	0.440
YAP1	CDIP1	psi-mi:“MI:0407”(direct interaction)	0.440
CDIP1	CCR2	psi-mi:“MI:0915”(physical association)	0.370
CDIP1	ATXN1	psi-mi:“MI:0915”(physical association)	0.370
CDIP1	UBQLN1	psi-mi:“MI:0915”(physical association)	0.000
LAT	CDIP1	psi-mi:“MI:0915”(physical association)	0.000
CDIP1	UBQLN2	psi-mi:“MI:0915”(physical association)	0.000
CDIP1	EPN2	psi-mi:“MI:0915”(physical association)	0.000
CDIP1	UBC	psi-mi:“MI:0915”(physical association)	0.000
CDIP1	OTUD7B	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (19): CDIP1 (Two-hybrid), CDIP1 (Two-hybrid), CDIP1 (Affinity Capture-RNA), CDIP1 (Two-hybrid), CDIP1 (Two-hybrid), CDIP1 (Two-hybrid), OTUB2 (Two-hybrid), DESI1 (Two-hybrid), UBQLN1 (Two-hybrid), UBC (Two-hybrid), UBB (Two-hybrid), UBQLN2 (Two-hybrid), LAT (Two-hybrid), OTUD7B (Two-hybrid), CDIP1 (Synthetic Rescue)

ESM2 similar proteins: A0JNC2, A1KXE4, A8E639, A8MV65, D4AEP3, E3X5D6, P05411, P12981, P18870, P54864, P60486, Q08BY2, Q0IHC4, Q0VFP2, Q14157, Q15032, Q15038, Q157S1, Q16656, Q3LRZ1, Q3T0A9, Q3T0K9, Q3U182, Q4R5H7, Q53ET0, Q58D45, Q5BJ83, Q5R526, Q5RDV6, Q5U2U6, Q5XIH2, Q5ZIS9, Q68ED7, Q6PEH8, Q7PXU6, Q80TM6, Q80X50, Q80XQ8, Q8AVW3, Q8BGZ2

Diamond homologs: A0A1B0GVX0, P0C0T0, Q54HX8, Q58D45, Q5BJ83, Q5U2U6, Q6GMG8, Q6P828, Q8AVW3, Q8QGW7, Q99732, Q9DB75, Q9H305, Q9JLJ0, Q6GZQ0

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 17 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Ovarian tumor domain proteases	5	99.5×	2e-07
Cargo recognition for clathrin-mediated endocytosis	5	37.4×	1e-05

Disease & clinical

Clinical variants and AI predictions

ClinVar

44 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	32
Likely benign	4
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1279 predictions. Top by Δscore:

Variant	Effect	Δscore
16:4512681:CAT:C	acceptor_gain	1.0000
16:4512682:ATCT:A	acceptor_loss	1.0000
16:4512683:TCT:T	acceptor_loss	1.0000
16:4512684:C:CC	acceptor_gain	1.0000
16:4512684:CTGA:C	acceptor_loss	1.0000
16:4512690:C:CT	acceptor_gain	1.0000
16:4512789:ACC:A	donor_gain	1.0000
16:4512790:CCC:C	donor_gain	1.0000
16:4512816:G:C	donor_gain	1.0000
16:4513848:CGGC:C	acceptor_gain	1.0000
16:4513853:T:A	acceptor_loss	1.0000
16:4513857:C:CT	acceptor_gain	1.0000
16:4514145:C:CC	acceptor_gain	1.0000
16:4514151:A:C	acceptor_gain	1.0000
16:4514569:TCTTA:T	donor_loss	1.0000
16:4514570:CTTA:C	donor_loss	1.0000
16:4514571:TTACC:T	donor_loss	1.0000
16:4514572:TACCT:T	donor_loss	1.0000
16:4514573:ACC:A	donor_loss	1.0000
16:4514574:C:CG	donor_loss	1.0000
16:4514671:C:CT	acceptor_gain	1.0000
16:4512679:CACAT:C	acceptor_gain	0.9900
16:4512682:AT:A	acceptor_gain	0.9900
16:4512685:T:C	acceptor_loss	0.9900
16:4512691:A:T	acceptor_gain	0.9900
16:4512786:CCTA:C	donor_loss	0.9900
16:4512787:CTAC:C	donor_loss	0.9900
16:4512788:TAC:T	donor_loss	0.9900
16:4512789:A:AC	donor_gain	0.9900
16:4512789:A:AG	donor_loss	0.9900

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000046113 (16:4537465 G>A), RS1000322333 (16:4513962 T>A), RS1000546731 (16:4518435 G>A), RS1000656835 (16:4512751 C>G,T), RS1000690968 (16:4519029 T>G), RS1000701166 (16:4535256 ACCC>A), RS1000725853 (16:4538835 T>TG), RS1000764779 (16:4535559 C>G,T), RS1000941240 (16:4532376 A>T), RS1001007557 (16:4520526 T>C,G), RS1001134990 (16:4525692 G>A), RS1001169787 (16:4518690 T>C), RS1001188144 (16:4520467 T>C), RS1001214774 (16:4537685 C>G), RS1001318895 (16:4537623 G>A)

Disease associations

OMIM: gene MIM:610503 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): breast ductal adenocarcinoma (MONDO:0005590)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

9 associations (top):

Study	Trait	p-value
GCST004946_101	Schizophrenia	5.000000e-09
GCST012227_378	Hip circumference adjusted for BMI	4.000000e-08
GCST012490_509	Femur bone mineral density x serum urate levels interaction	4.000000e-08
GCST90002382_429	Eosinophil percentage of white cells	7.000000e-10
GCST90020024_738	A body shape index	3.000000e-10
GCST90020025_201	Waist-to-hip ratio adjusted for BMI	3.000000e-08
GCST90020025_202	Waist-to-hip ratio adjusted for BMI	3.000000e-08
GCST90020027_656	Waist-hip index	2.000000e-08
GCST90020027_657	Waist-hip index	4.000000e-08

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0008039	BMI-adjusted hip circumference
EFO:0004531	urate measurement
EFO:0007991	eosinophil percentage of leukocytes
EFO:0007789	BMI-adjusted waist circumference
EFO:0007788	BMI-adjusted waist-hip ratio

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D018270	Carcinoma, Ductal, Breast	C04.557.470.200.025.232.500; C04.557.470.615.132.500; C04.588.180.390; C17.800.090.500.390

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

34 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, decreases methylation, increases expression, increases methylation	4
Aflatoxin B1	affects expression, increases expression, increases methylation	4
FR900359	decreases phosphorylation	1
dicrotophos	increases expression	1
propionaldehyde	increases expression	1
sodium arsenite	increases expression	1
butyraldehyde	increases expression	1
pentanal	increases expression	1
di-n-butylphosphoric acid	affects expression	1
nutlin 3	increases expression, affects cotreatment	1
abrine	increases expression	1
jinfukang	affects cotreatment, increases expression	1
prothioconazole	decreases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Acetaminophen	increases expression	1
Air Pollutants	decreases expression, increases abundance	1
Aldehydes	increases expression	1
Atrazine	decreases expression	1
Camptothecin	increases expression	1
Cisplatin	affects cotreatment, increases expression	1
Dactinomycin	affects cotreatment, increases expression	1
Dimethyl Sulfoxide	decreases expression	1
Doxorubicin	increases expression	1
Ethyl Methanesulfonate	increases expression	1
Formaldehyde	increases expression	1
Methyl Methanesulfonate	increases expression	1
Plant Extracts	affects cotreatment, decreases expression	1
Quercetin	increases expression	1
Silicon Dioxide	increases expression	1
Smoke	decreases expression, increases abundance	1

Clinical trials (associated diseases)

11 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT03414970	PHASE3	ACTIVE_NOT_RECRUITING	Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
NCT00461344	PHASE2	TERMINATED	Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer
NCT07499999	PHASE2	NOT_YET_RECRUITING	Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer
NCT00637364	PHASE1/PHASE2	SUSPENDED	High Intensity Focused Ultrasound Tumor Treatment for Pancreatic Cancer Pain
NCT02779855	PHASE1/PHASE2	COMPLETED	Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
NCT01753908	EARLY_PHASE1	COMPLETED	Broccoli Sprout Extract in Treating Patients With Breast Cancer
NCT01796041	EARLY_PHASE1	COMPLETED	Intraoperative Imaging of Breast Cancer With Indocyanine Green
NCT01208974	Not specified	ACTIVE_NOT_RECRUITING	Nipple-Areola Complex (NAC) Irradiation After Nipple-Sparing Mastectomy and Reconstruction
NCT01875198	Not specified	TERMINATED	Oncologic Impact of Splenectomy-omitting Radical Pancreatectomy in Well-selected Left-sided Pancreatic Cancer
NCT03543397	Not specified	UNKNOWN	MRI in Ductal Carcinoma in Situ (DCIS)
NCT03834532	Not specified	COMPLETED	Living Well After Breast Surgery